drugset / Trial / NCT06959979
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma
Phase 0
Recruiting
60 enrolled
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello · collabUniversity of Rome Tor Vergata · collabUniversità degli Studi di Enna Kore · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Medulloblastoma (MB), a rare yet critical pediatric brain tumor, is divided into 4 molecular subgroups (WNT, SHH, Group 3, Group 4), each with distinct genetic profiles. Despite diagnostic and therapeutic advances, neurotoxicity from standard treatments (resection, radiotherapy, chemotherapy) and the need for long-term care remain challenges. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), approved for breast cancer, show potential in other tumors, but their efficacy in MB is unclear. Treatment resistance is a concern. This project aims to identify genetic markers of sensitivity to CDK4/6 inhibitors in MB, to improve therapies and overcome resistance.
Timeline
- Start
- 2024-11-25
- Primary completion
- 2026-08-31
- Completion
- 2026-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abemaciclib | Small molecule | 0.19 unknown | — |
| Subject | Palbociclib | Small molecule | 0.07 unknown | — |
| Subject | Ribociclib | Small molecule | — | — |